AIKIDO PHARMA INC (AIKI) 6.23 -0.07 (-1.11%)
6.23 -0.07 (-1.11%)
US0088753043 - Common Stock
Fundamental Rating
We assign a fundamental rating of 4 out of 10 to AIKI. AIKI was compared to 644 industry peers in the Biotechnology industry. While AIKI has a great health rating, but there are worries on its profitability. AIKI is valued expensive and it does not seem to be growing.
Profitability
Profitability Rating
AIKI's Return On Assets of -5.72% is amongst the best returns of the industry. AIKI outperforms 90% of its industry peers. The industry average Return On Assets is -40.38%.
AIKI has negative profitability rations, so we won't be analyzing them here.
AIKI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of AIKI.
VS Industry
ROA (-5.72%) VS Industry: 90% outperformed.
-1,226.49
115.38
Valuation
Valuation Rating
With a price book ratio of 0.28, AIKI is valued rather cheaply.
Compared to an average industry price book ratio of 1.93, AIKI is valued rather cheaply. On top of this, AIKI is cheaper than 98% of the companies listed in the same industry.
The Price/Earnings Ratio is negative for AIKI. In the last year negative earnings were reported.
Also next year AIKI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the Enterprise Value to EBITDA ratio of AIKI to the average industry ratio of 0.77, AIKI is valued more expensive than its industry peers.
VS Industry
Price/Book (0.28) VS Industry: 98% outperformed.
669.86
0.07
Enterprise Value/ EBITDA (3.44) VS Industry: 22% outperformed.
4,992.29
0.00
Growth
Growth Rating
Based on estimates for the next 5 years, AIKI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.69% on average per year.
The earnings per share for AIKI have decreased strongly by -596.19% in the last year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -596.19% | 84.56% | 38% | 25.87% | 14.69% |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
A Current Ratio of 110.82 indicates that AIKI has no problem at all paying its short term obligations.
The Current Ratio of AIKI is much better than the industry average of 6.69. AIKI has a better rating than 99% of its industry peers.
A Quick Ratio of 110.82 indicates that AIKI has no problem at all paying its short term obligations.
AIKI is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.55. AIKI has a better rating than 99% of its industry peers.
AIKI has an Altman-Z score of 20.37. This indicates that AIKI is financially healthy and little risk of bankruptcy at the moment.
AIKI has one of the better Altman-Z scores in its industry. It is much better than the industry average of 0.49. AIKI has a better score than 91% of its industry peers.
The Debt to Equity ratio of AIKI is in line with the industry averages.
The Piotroski-F score of AIKI is 3.00. This is a low score and indicates issues in the health and profitability of AIKI.
VS Industry
Debt/Equity (0) VS Industry: 42% outperformed.
18.24
0.00
Quick Ratio (110.82) VS Industry: 99% outperformed.
0.04
138.86
Current Ratio (110.82) VS Industry: 99% outperformed.
0.15
140.77
Altman-Z (20.37) VS Industry: 91% outperformed.
-253.58
1,332.86
Dividend
Dividend Rating
AIKI does not give a dividend.
AIKIDO PHARMA INC6.23
NASDAQ:AIKI (8/16/2022, 7:15:40 PM)-0.07 (-1.11%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 05-16 2022-05-16/dmh | Earnings (Next) | 08-23 2022-08-23/amc |
| Ins Owners | 6.19% | Inst Owners | 13.66% |
| Market Cap | 32.72M | Analysts | 82.86 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | N/A | P/B | 0.28 |
| EV/EBITDA | 3.44 | ||
| ROA | -5.72% | ROE | N/A |
| PM | N/A | Asset Turnover | N/A |
| EPS 1Y | -596.19% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -871.43% |
| EPS Next Y | 84.56% | EPS Next 2Y | 38% |
| EPS Next 3Y | 25.87% | EPS Next 5Y | 14.69% |
| Revenue growth 1Y | N/A | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| Current Ratio | 110.82 | Quick Ratio | 110.82 |
| Altman-Z | 20.37 | F-Score | 3 |
| Debt/Equity | 0 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA